Business
PCA Dealing
Venture Life Group PLC announced that Lewis Arthur, acting as a person closely associated with Sarah Arthur, the Interim Commercial Director, purchased 2,959 ordinary shares at 67.38 pence per share on January 29, 2026. This transaction brings Sarah Arthur's total beneficial interest, including those held by her PCA, to 2,959 ordinary shares, representing 0.002% of the company's issued share capital. Disclaimer*

About this update from Venture Life Group Plc
12 February 2026 VENTURE LIFE GROUP PLC ("Venture Life", "VLG" or the "Group") PCA Dealing Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy, product innovation, development, and commercialisation within the global consumer healthcare sector, announces that it was notified on 11 February 2026 that Lewis Arthur, a PCA of Sarah Arthur, Interim Commercial Director of the Company, purchased 2,959 ordinary shares of 0.3 pence each in the capital of the Company (" Ordinary Shares ") at a price of 67.38p per Ordinary Share on 29 January 2026 (the " Purchase "). Following the Purchase, Sarah Arthur's beneficial interest in the Company, including those held by her PCA, is 2,959 Ordinary Shares, representing 0.002 per cent. of the issued share capital of the Company. For further information, please contact: Venture Life Group PLC +44 (0) 1344 578004 Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 Stephen Keys/George Lawson (Corporate Finance) Michael Johnson (Sales) About Venture Life ( www.venture-life.com ) Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. The notification below, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018), provide further detail on the share dealings. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Lewis Arthur 2 Reason for the notification a) Position/status PCA of Sarah Arthur, Interim Commercial Director b) Initial notification /Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Venture Life Group plc b) LEI 213800S8CZUPLAB2KC70 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of 0.3p each in Venture Life Group plc GB00BFPM8908 b) Nature of the transaction Purchase of Ordinary Shares c) Price(s) and volume(s) Price Volume 67.38 pence 2,959 d) Aggregated information - Aggregated volume - Price N/A - Single transaction e) Date of the transaction 29 January 2026 f) Place of the transaction London Stock Exchange
View stock analysis, news, and events for Venture Life Group Plc